Ameriflex Group Inc. Purchases 525 Shares of Novo Nordisk A/S $NVO

Ameriflex Group Inc. increased its position in Novo Nordisk A/S (NYSE:NVO) by 8.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,511 shares of the company’s stock after purchasing an additional 525 shares during the period. Ameriflex Group Inc.’s holdings in Novo Nordisk A/S were worth $441,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of NVO. QRG Capital Management Inc. lifted its stake in Novo Nordisk A/S by 0.6% during the 2nd quarter. QRG Capital Management Inc. now owns 232,716 shares of the company’s stock valued at $16,062,000 after acquiring an additional 1,480 shares in the last quarter. Segment Wealth Management LLC lifted its stake in Novo Nordisk A/S by 2.4% during the 2nd quarter. Segment Wealth Management LLC now owns 160,668 shares of the company’s stock valued at $11,089,000 after acquiring an additional 3,751 shares in the last quarter. Ameritas Advisory Services LLC lifted its stake in Novo Nordisk A/S by 41.1% during the 2nd quarter. Ameritas Advisory Services LLC now owns 4,977 shares of the company’s stock valued at $344,000 after acquiring an additional 1,449 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Novo Nordisk A/S by 3.6% during the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 6,760 shares of the company’s stock valued at $467,000 after acquiring an additional 232 shares in the last quarter. Finally, Copeland Capital Management LLC lifted its stake in Novo Nordisk A/S by 47.3% during the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after acquiring an additional 186 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on NVO shares. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Finally, Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $77.50.

Novo Nordisk A/S Trading Up 1.6%

Shares of NVO opened at $59.68 on Friday. The business has a 50-day moving average of $54.92 and a 200 day moving average of $63.84. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $120.56. The firm has a market cap of $266.45 billion, a P/E ratio of 16.39, a price-to-earnings-growth ratio of 2.25 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.